Jasper Therapeutics Files Routine 8-K on Jan 2, 2024
Ticker: JSPRW · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, regulation-fd, financial-statements
TL;DR
**JSPR filed a routine 8-K, nothing major to report.**
AI Summary
Jasper Therapeutics, Inc. filed an 8-K on January 2, 2024, to report a routine event, specifically a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates no major new financial or operational news, but rather a standard update to ensure fair disclosure of information. For investors, this means there's no immediate significant positive or negative news impacting the stock, and it's a standard compliance filing.
Why It Matters
This filing is a standard compliance update, indicating no immediate material changes to Jasper Therapeutics' financial health or operations, which can reassure investors of business as usual.
Risk Assessment
Risk Level: low — This 8-K is a standard, routine filing with no disclosed events that would introduce new risks or significant changes.
Analyst Insight
A smart investor would note this as a routine compliance filing and look for more substantive 8-K filings or other SEC documents for material news regarding Jasper Therapeutics, Inc. before making investment decisions.
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 2, 2024 (date) — date of earliest event reported and filing date
- 001-39138 (string) — Commission File Number
- 84-2984849 (string) — IRS Employer Identification No.
- 2200 Bridge Pkwy Suite #102 Redwood City, California 94065 (string) — Address of Principal Executive Offices
- 650-549-1400 (string) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Jasper Therapeutics, Inc.?
The purpose of this 8-K filing by Jasper Therapeutics, Inc. is to report a Regulation FD Disclosure and to include Financial Statements and Exhibits, as indicated under 'ITEM INFORMATION' in the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 2, 2024, which is also the date of the report.
What is the state of incorporation for Jasper Therapeutics, Inc.?
Jasper Therapeutics, Inc. is incorporated in Delaware, as stated in the filing under 'State or Other Jurisdiction of Incorporation'.
What is the business address of Jasper Therapeutics, Inc.?
The business address of Jasper Therapeutics, Inc. is 2200 Bridge Pkwy Suite #102, Redwood City, California 94065, according to the filing.
Does this 8-K filing indicate any significant new financial or operational news for Jasper Therapeutics, Inc.?
No, this 8-K filing does not indicate any significant new financial or operational news. It primarily covers a Regulation FD Disclosure and Financial Statements and Exhibits, which are often routine compliance items, and does not detail any specific material events that would suggest major changes.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-02 08:05:09
Key Financial Figures
- $0.0001 — tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
- $11.50 — ng Common Stock at an exercise price of $11.50 JSPRW The Nasdaq Stock Market LLC
Filing Documents
- ea190805-8k_jasper.htm (8-K) — 29KB
- ea190805ex99-1_jasper.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-000056.txt ( ) — 274KB
- jspr-20240102.xsd (EX-101.SCH) — 4KB
- jspr-20240102_def.xml (EX-101.DEF) — 26KB
- jspr-20240102_lab.xml (EX-101.LAB) — 36KB
- jspr-20240102_pre.xml (EX-101.PRE) — 25KB
- ea190805-8k_jasper_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 2, 2024, Jasper Therapeutics, Inc. issued a press release with respect to a pending reverse split of its voting common stock. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report"). The information contained in this Item 7.01 of this Current Report, including Exhibit 99.1 hereto, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Item 7.01 of this Current Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated January 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JASPER THERAPEUTICS, INC. Date: January 2, 2024 By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 2